NL-OMON51116尚未招募3 期
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo - TRuE-V LTE Study
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 至 99（—）
入选标准
- •1. Currently enrolled and receiving treatment in INCB 18424-306 or INCB
- •18424-307 studies evaluating ruxolitinib cream in participants with vitiligo.
- •2. Currently tolerating ruxolitinib cream in the parent study and no safety
- •concerns per investigators judgment.
- •3. Has demonstrated compliance, as assessed by the investigator, with the
- •parent study protocol requirements
排除标准
- •1. Has been permanently discontinued from study treatment in the parent study
- •for any reason.
- •2. Participants with an uncontrolled intercurrent illness or any concurrent
- •condition that, in the investigator's opinion, would jeopardize the safety of
- •the participant or compliance with the Protocol. 3. Pregnant or breastfeeding
研究者
相似试验
进行中（未招募）
1 期
ong-Term Efficacy and Safety Study of Ruxolitinib Cream in Participants With VitiligoVitiligoMedDRA version: 21.1Level: PTClassification code 10047642Term: VitiligoSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2020-000987-53-DEIncyte Corporation500
进行中（未招募）
1 期
ong-Term Efficacy and Safety Study of Ruxolitinib Cream in Participants With VitiligoEUCTR2020-000987-53-NLIncyte Corporation500
进行中（未招募）
1 期
ong-Term Efficacy and Safety Study of Ruxolitinib Cream in Participants With VitiligoEUCTR2020-000987-53-FRIncyte Corporation500
进行中（未招募）
1 期
ong-Term Efficacy and Safety Study of Ruxolitinib Cream in Participants With VitiligoVitiligoMedDRA version: 21.1Level: PTClassification code 10047642Term: VitiligoSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2020-000987-53-PLIncyte Corporation500
进行中（未招募）
1 期
ong-Term Efficacy and Safety Study of Ruxolitinib Cream in Participants With VitiligoEUCTR2020-000987-53-BGIncyte Corporation500